Ethylbenzodioxolylbutanamine

Ethylbenzodioxolylbutanamine (EBDB), also known as Butylone, is a psychoactive drug and research chemical of the phenethylamine, amphetamine, and cathinone chemical classes. It is structurally related to entactogens such as MDMA, MBDB, and MDEA.

History

EBDB was first synthesized by Koichi Shulgin in 1969. It was then rediscovered in 2004 by a team at the University of California, Berkeley. Since then, it has been used as a recreational drug, often sold as "legal MDMA" or "legal ecstasy".

Pharmacology

EBDB acts as a mixed reuptake inhibitor/releasing agent of serotonin, norepinephrine, and dopamine. These are all neurotransmitters in the brain that play important roles in mood, cognition, and motivation. EBDB is thought to produce its psychoactive effects by increasing the levels of these neurotransmitters in the synapses of the brain.

Effects

The effects of EBDB are similar to those of other entactogens and stimulants. These effects include euphoria, increased sociability, mental and physical stimulation, enhanced appreciation of music, and increased sensory awareness. However, EBDB also has potential side effects, including insomnia, heart palpitations, hypertension, and sweating.

Legal Status

The legal status of EBDB varies by country. In the United States, it is a Schedule I controlled substance. In the United Kingdom, it is a Class B drug. In Canada, it is a Schedule III drug. In Australia, it is a Schedule 9 prohibited substance.

See Also

• MDMA
• MBDB
• MDEA
• Methylone
• Buphedrone